UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  May 14, 2021 (May 13, 2021)

 

 

Repare Therapeutics Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Québec   001-39335   Not applicable

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

7210 Frederick-Banting, Suite 100

St-Laurent, Québec, Canada

  H4S 2A1
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code:  (857) 412-7018

Not Applicable

(Former Name or Former Address, if Changed Since Last Report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading Symbol

  

Name of each exchange

on which registered

Common shares, no par value    RPTX    The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.07

Submission of Matters to a Vote of Security Holders.

On May 13, 2021, Repare Therapeutics Inc., a corporation governed by the Business Corporations Act (Québec) (the “Company”) held its Annual Meeting of Shareholders (“Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on the two proposals set forth below. A more detailed description of each proposal is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 1, 2021.

Proposal 1 – Election of Directors

Jerel Davis, Ph.D., Todd Foley and Ann D. Rhoads were each elected to serve as a Class I director of the Company’s Board of Directors until the 2024 Annual Meeting of Shareholders and until his or her successor is duly elected or until his or her earlier resignation or removal, by the following votes:

 

Nominee

 

Votes For

 

Votes Withheld

 

Broker Non-Votes

Jerel Davis, Ph.D.

  29,759,115   3,122,873   1,364,632

Todd Foley

  29,731,331   3,150,657   1,364,632

Ann D. Rhoads

  32,845,796        36,192   1,364,632

Proposal 2 – Appointment of Independent Registered Public Accounting Firm

The shareholders approved the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021, by the following votes:

 

Votes For   Votes Against   Votes Withheld
34,244,251   2,289   80


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

REPARE THERAPEUTICS INC.

By:

 

/s/  Lloyd M. Segal

 

Lloyd M. Segal

President and Chief Executive Officer

Dated: May 14, 2021